Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Jun 30, 2018
Mar 31, 2018
Dec 31, 2017
Sep 30, 2017
Total Revenue
372,845
373,447
358,305
334,148
Cost of Revenue
79,019
82,333
75,995
59,480
Gross Profit
293,826
291,114
282,310
274,668
Operating Expenses
Research Development
175,582
183,948
168,608
154,103
Selling General and Administrative
153,280
138,336
160,280
130,532
Non Recurring
--
--
--
--
Others
10,227
13,202
20,375
3,760
Total Operating Expenses
339,089
335,486
349,263
288,395
Operating Income or Loss
(45,263)
(44,372)
(66,953)
(13,727)
Income from Continuing Operations
Total Other Income/Expenses Net
22,742
(104)
128,393
14
Earnings Before Interest And Taxes
(16,952)
(47,843)
62,537
(9,737)
Interest Expense
12,225
2,961
7,939
10,884
Income Before Tax
(29,177)
(50,804)
54,598
(20,621)
Income Tax Expense
(12,385)
(6,655)
105,990
(8,094)
Minority Interest
--
--
--
--
Net Income From Continuing Ops
(16,792)
(44,149)
(51,392)
(12,527)
Non-recurring Events
Discontinued Operations
--
--
--
--
Extraordinary Items
--
--
--
--
Effect Of Accounting Changes
--
--
--
--
Other Items
0
0
0
0
Net Income
(16,792)
(44,149)
(51,392)
(12,527)
Preferred Stock And Other Adjustments
--
--
--
--
Net Income Applicable To Common Shares
(16,792)
(44,149)
(51,392)
(12,527)

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information